New Immune Therapy Boosts Disease Control in Prostate Cancer

Published Date: 19 Jun 2026

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

Read Full News

Latest News

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

Todays Updates

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

Todays Updates

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

Latest News

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

News All Time

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Breast Density Laws Fall Short Raising Additional Screening

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

Prostate cancer death risk is higher in late teens and early 20s weight gain.

Study suggests exercise could reduce breast cancer recurrence

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

3.

New Gene Therapy Nears EU Nod for Bladder Cancer

4.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

5.

Cancer research in the US is world class. With the government pulling out, its future is uncertain

1.

A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia

2.

Emerging Models in Oncology for Specialists

3.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

4.

Regenerative Reprogramming of Dormant Cellular Niches Following Cancer Therapy

5.

Emerging Advances in Hematology and Quality Improvement

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Signs and Symptoms of Leukemia

2.

Clinical Insights in Oncology

3.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

4.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

5.

Immunotherapy: A New Era in Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

New Immune Therapy Boosts Disease Control in Prostate Cancer

Latest News

NPM1-Mutated AML: Not All Treatments Are Equal

Transgender Individuals Prefer HPV Self-Swabs

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

FDA Approves Iberdomide Combo for Multiple Myeloma

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Wide Variation Seen in Lung Screening False-Positive Rates

Todays Updates

Belgian Algorithm Reshapes Endometrial Cancer Care

Todays Updates

Belgian Algorithm Reshapes Endometrial Cancer Care

Latest News

News All Time

AI Framework Helps Classify Renal Tumors, Predict Outcomes

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Breast Density Laws Fall Short Raising Additional Screening

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Trial Challenges Indefinite Maintenance for Multiple Myeloma

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

Transperineal Biopsy IDs Active Surveillance Candidates

The Clues Hidden in Failed Prostate Cancer Trials

Palliative Care Remains Uncommon in Young Adults With Cancer

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

Stem Cell Transplant Associated With Better PFS in NKTCL

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

Recommended News For You

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study